New Orleans, LA, USA—May 22, 2019—ISPOR the professional society for health economics and outcomes research (HEOR), examined the issue of patient access and biosimilars this afternoon at its ISPOR 2019 annual conference with the session [W20], "Improving Patient Access to Life Saving Therapies: What Needs to Be Done to Fulfill the Promise of Biosimilars?"
Discussion leaders for
the workshop session included:
- Delphine Courmier, PhD, MBA; Amgen; Thousand Oaks, CA, USA
- Cate Lockhart, PharmD, PhD; Biologics and Biosimilars Collective
Intelligence Consortium; Greenbank, WA, USA
- Steven Simoens, MSc, PhD; KU Leuven; Leuven, Belgium
- Jacqueline Vanderpuye-Orgle,
PhD; Parexel; Glendale, CA, USA
Biosimilars hold the
promise of reducing healthcare costs and improving patient access to
life-saving biologics. In Europe, robust market competition has resulted in
savings to healthcare systems. However, tremendous variation exists across
countries in the adoption of biosimilars.
Professor Simoens provided
an overview of the current biosimilars landscape in Europe, including the gaps
and challenges that exist, such as the choice of analytical approach, managed
entry agreements, and the use of value-added services. Dr Vanderpuye-Orgle discussed
the factors that may contribute to suboptimal adoption of biosimilars in the
United States, including approval process and payer expectations. Dr Lockhart noted
studies show that physicians’ concerns regarding biosimilars include insufficient
guidance on switching, evolving standards of care, and patient-level outcomes. She
also pointed out that patients worry about manufacturer quality, long-term
safety and efficacy, and imperfect understanding of rapidly evolving concepts.
Dr Courmier outlined the manufacturer perspective of biosimilars.
ISPOR is recognized
globally as the leading professional society for health economics and outcomes
research and its role in improving healthcare decisions. ISPOR 2019 is the
leading global HEOR conference and draws nearly 4000 healthcare thought leaders
and stakeholders, including researchers and academicians, assessors and
regulators, payers and policy makers, the life sciences industry, healthcare
providers, and patient engagement organizations.
Additional information on the conference can be found at:
Conference Information | Program | Registration | Short Course Program | Sponsors | Exhibitors | Press
###
ABOUT
ISPOR
ISPOR, the professional society for health economics
and outcomes research (HEOR), is an international, multistakeholder, nonprofit
dedicated to advancing HEOR excellence to improve decision making for health
globally. The Society is the leading source for scientific conferences,
peer-reviewed and MEDLINE®-indexed publications, good practices
guidance, education, collaboration, and tools/resources in the field.
Web: www.ispor.org | LinkedIn: www.linkedin.com/company/ispororg | Twitter: www.twitter.com/ispororg (@ISPORorg) | YouTube: www.youtube.com/ispororg | Facebook: www.facebook.com/ispororg | Instagram: www.instagram.com/ispororg